Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 18/20 | 1.00 |
| ▸ | CCR7 | P32248 | 1/20 | 0.81 |
| ▸ | CCR6 | P51684 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574856 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL1446663 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL184744 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL12262719 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262756 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024684 | 0.89 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262817 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262770 | 0.89 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 | |
| Navarixin Anhydrous SCHEMBL2024683 | 0.89 | CXCR2 (0.98) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12262798 | 0.88 | CXCR2 (1.00) | CXCR2CXCR1CCR7CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588092-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012001076-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | claimed |
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-09-05 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1818325-B1 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORP (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | AQP3, SUCNR1, AQP1 | CXCR2 3127/4885CXCR1 1617/4885CCR7 2877/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR7 15/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR7 15/4885 |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885CCR7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.